(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.36%) $82.71
(6.71%) $2.05
(0.04%) $2 348.20
(-0.35%) $27.44
(4.08%) $959.75
(-0.23%) $0.933
(-0.33%) $10.99
(-0.53%) $0.796
(1.55%) $93.30
@ $1.954
发出时间: 14 Feb 2024 @ 22:32
回报率: -26.56%
上一信号: Feb 8 - 05:00
上一信号:
回报率: 1.24 %
Live Chart Being Loaded With Signals
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers...
Stats | |
---|---|
今日成交量 | 340 932 |
平均成交量 | 430 161 |
市值 | 50.21M |
EPS | $0 ( 2024-04-04 ) |
下一个收益日期 | ( $-0.370 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.450 |
ATR14 | $0.00500 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fortress Biotech, Inc. | Buy | 193 905 | COMMON STOCK, PAR VALUE $0.0001 |
2024-03-12 | Amit Sharma | Sell | 0 | Common Stock (Restricted) |
2024-02-28 | Oliviero James F Iii | Sell | 5 894 | COMMON STOCK |
2024-02-28 | Oliviero James F Iii | Sell | 9 056 | COMMON STOCK |
2024-02-28 | Gray William Garrett | Sell | 2 035 | Common Stock |
INSIDER POWER |
---|
82.65 |
Last 98 transactions |
Buy: 5 337 828 | Sell: 1 367 663 |
音量 相关性
Checkpoint Therapeutics 相关性 - 货币/商品
Checkpoint Therapeutics 财务报表
Annual | 2023 |
营收: | $103 000 |
毛利润: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2023 |
营收: | $103 000 |
毛利润: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2022 |
营收: | $192 000 |
毛利润: | $-49.63M (-25 850.52 %) |
EPS: | $-7.57 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-10.15 |
Financial Reports:
No articles found.
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。